New clinical data for left atrial appendage occlusion therapy, presented & published in 2016. Includes a critical review of the Stroke Prevention section in the 2016 ESC Atrial Fibrillation guidelines.
Why might LAA occlusion therapy be cost effective, despite a high procedural cost? This presentation is an overview of the health economics data available for left atrial appendage closure therapy.
The Neurologist point of view: review of the published evidence and the consensus on bleeding+stroke risk assessments in AF patients. when approaching antithrombotic therapy in AF patients. Includes uptake of the LAAO recommendation in the ESC guidelines and what that means to Neurologists. Many Cardiologists do not really know what Neurologist think and the reasoning. What it does it mean to the every day practice, and the annual number of ICH on NOAC or VKA for the average neurology practice?
Driving factors and main considerations for the LAA occlusion consensus papers (including EHRA/EAPCI and others). This includes a summary of main recommendations, including training & proctoring. What does this document mean for the average implanting cardiologist and follow-up physician?
Which data is published since January 2015? Includes papers on LAAO, but also key results from other stroke prevention trials and analysis. SHOW MORE
Bleeding and Stroke Risk Assessment in Atrial Fibrillation: Choosing between Warfarin, NOACS, Antiplatelets, or Nothing? Has the role of LAAO changed in the recent years? How does LAAO compare to the NOAC?
Driving factors and main considerations for the LAA occlusion consensus paper = summary of main recommendations, including training & proctoring. What does this document mean for the average implanting cardiologist and follow-up physician?
Debate - Protagonist. LAA occlusion should be considered for (N)OAC in-tolerant patients primarily.
Debate - Anttagonist. LAA occlusion should be considered for (N)OAC in-tolerant patients primarily. NO, it should be for everyone!
